The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Previous

Neither Fame Nor Fortune Protects Against Hep C

Back to News Homepage

Next

Hep C News: Milk Thistle Research Confirms Liver Benefit

Price of New Hep C Drugs Still Under Scrutiny

Print this page

How much will treatment cost for the newly approved Hepatitis C drugs? Will patients in developing countries be able to afford it?
Price of New Hep C Drugs Still Under Scrutiny Pin it on Pinterest

Pharma & Healthcare

11/11/2013 @ 5:39PM

Will The New Hepatitis C Drugs Trigger A Battle Over Cost?

As excitement mounts among physicians and investors over a new batch of drugs for treating hepatitis C, there is also concern that patients in developing countries may not have sufficient access due to high prices. But a recent poster presentation at a medical conference suggests that drugmakers can produce these new medicines for relatively little cost and should be compelled to do so.

The analysis, which was displayed at the American Association for the Study of Liver Diseases gathering last week in Washington, DC, concluded that large-scale production of direct acting antivirals may be possible for as little as $100 to $200 for 12 weeks of treatment. The estimate cited HIV drugs, which initially cost tens of thousands of dollar per patient but have since dropped significantly in price in developing nations, as a model framework.

Continue reading this entire article:
http://www.forbes.com/sites/edsilverman/2013/11/11/will-the-new-hepatitis-c-drugs-trigger-a-battle-over-cost/

2 Comments
Share
Share

Previous

Neither Fame Nor Fortune Protects Against Hep C

Back to News Homepage

Next

Hep C News: Milk Thistle Research Confirms Liver Benefit

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.